# Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice

> **NCT05928286** · — · COMPLETED · sponsor: **POLYSAN Scientific & Technological Pharmaceutical Company** · enrollment: 286 (actual)

## Conditions studied

- Gallstone Disease
- Obstructive Jaundice

## Interventions

- **DRUG:** Remaxol

## Key facts

- **NCT ID:** NCT05928286
- **Lead sponsor:** POLYSAN Scientific & Technological Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 286 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05928286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05928286, "Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05928286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*